[Current results of the treatment of pseudoparalytic myasthenia gravis with immunosuppressive agents].
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000328:Adult; D000906:Antibodies; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007111:Immunity, Cellular; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008875:Middle Aged; D009124:Muscle Proteins; D009157:Myasthenia Gravis / Q000150:complications / Q000188:drug therapy*; D009218:Myosins; D012075:Remission, Spontaneous; D013945:Thymoma / Q000150:complications; D013952:Thymus Hyperplasia / Q000150:complications; D013953:Thymus Neoplasms / Q000150:complications
D000906:Antibodies; D000961:Antilymphocyte Serum; D002800:Cholinesterase Inhibitors; D007166:Immunosuppressive Agents; D009124:Muscle Proteins; D000324:Adrenocorticotropic Hormone; D015122:Mercaptopurine; D009218:Myosins; D001379:Azathioprine
Bisherige Behandlungsergebnisse der immunosuppressiven Therapie der Myasthenia gravis pseudoparalytica.